Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome.

Obesity (Silver Spring, Md.)·2026
Same author

Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.

The Lancet. Neurology·2026
Same author

The Genetic and Environmental Architecture of the Human Functional Connectome.

ArXiv·2026
Same author

Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome.

Neurology·2026
Same author

CMV Immune Responses and Cognitive Impairment in People with HIV.

The Journal of infectious diseases·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Julie K Wisch1, Nicole S McKay2, Matthew D Zammit3

  • 1Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

采样代局部近似 (SILA) 算法准确估计自自体主导性阿尔茨海默病 (ADAD) 中的粉样蛋白阳性以来的时间. 这项阿尔茨海默病 (AD) 研究使得更好的疾病阶段和AD形式之间的比较成为可能.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物医学成像技术 生物医学成像技术
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 阿尔茨海默氏病 (AD) 病理在几十年内进展,需要准确的治疗时间的分期.
  • 自体主导AD (ADAD) 允许通过估计的症状发作年数 (EYO) 预测症状发作,但这种方法缺乏广泛的适用性.
  • 对ADAD的验证,广泛适用的时间过程对于了解疾病进展和干预策略至关重要.

研究的目的:

  • 验证采样代局部近似 (SILA) 算法,使用具有已知的疾病时间进程的队列.
  • 建立一种可靠的方法,以使用纵向PET数据来估计自自体主导AD (ADAD) 的粉样蛋白阳性 (A时间) 的时间.

主要方法:

  • 在长度ADAD队列 (N=316) 中使用PET数据评估A时间.
  • 对比新阳性个体的粉样蛋白阳性 (A+) 的SILA预测年龄与A+的观察年龄.
  • 利用线性回归和通用添加模型来比较A时间和EYO与症状发作和认知表现相关.

主要成果:

  • SILA在预测粉样蛋白阳性时的年龄方面显示了1.15年的平均平均误差.
  • 在A+时的SILA估计年龄解释了症状发作时估计年龄差异的39% (β=0.918,p<0.0001).
  • A时间解释了19%的认知变异,而EYO解释了43%,表明认知和疾病进展标志物之间存在非线性关联.

结论:

  • 该SILA算法提供了一个有效的时间估计从ADAD中粉样蛋白的阳性.
  • 这种验证可以直接比较ADAD分期与其他AD形式,克服EYO的局限性.
  • 在临床前阿尔茨海默氏症持续时间上存在显著的异质性,不仅仅是粉样蛋白状况,这突显了阿尔茨海默氏症进展的复杂性.